Magnevist

PreclinicalSmall molecule

Bayer

Magnevist is one of 9 small molecule programs targeting Magnetic Resonance Imaging. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Magnetic Resonance ImagingCompleted

Magnetic Resonance ImagingPreclinical

Completed

Competition

Competitive Landscape

9 competitors in Magnetic Resonance Imaging

#DrugCompanyPhaseTrials

Elucirem

GGuerbet

Approved

1 2

Minipress

Pfizer

Phase 2

2 3

Hyperpolarized 13c Pyruvate

UUniversity of Maryland, Baltimore

Phase 1

1 4

D-Cycloserine

MMassachusetts General Hospital

Preclinical

1 5

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 6

PSMA-11

NNational Cancer Institute (NCI)

Preclinical

1 7

PSMA-1007

AABX advanced biochemical compounds GmbH

Preclinical

1 8

Magnevist

Bayer

Preclinical

1 9

GLP-1 Agonists

MMedical College of Wisconsin

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Breast1 trial

Multihance Versus Magnevist in Breast MRI

Completed·BBracco Diagnostics, Inc·Phase 3·NCT00486473·130 enrolled

Central Nervous System1 trial

Safety and Efficacy Evaluation of DOTAREM® in MRI of Central Nervous System (CNS) Lesions

Completed·GGuerbet·Phase 3·NCT01211873·416 enrolled

Myocardial Infarction1 trial

Depiction of Delayed Enhancement in Patients With Documented Myocardial Infarction

Completed· Bayer logo

Bayer·Phase 2·NCT00310544·73 enrolled

Metastasis1 trial

Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Patients With Brain Metastasis

Completed· Bayer logo

Bayer·Phase 3·NCT00681551·45 enrolled

Magnetic Resonance Imaging1 trial

Magnetic Resonance Imaging Evaluation of Inner Ear Pathology Using Intra-Tympanic Contrast Agent

Completed·UUniversity of California, San Diego·N/A·NCT02080312·6 enrolled

4 more indications

MPA1 trial

Crossover Study With MultiHance vs a Comparator for Peripheral MRA

Completed·BBracco Diagnostics, Inc·Phase 3·NCT00408083·100 enrolled

Breast Cancer1 trial

Proton MR Spectroscopy and 18F-Fluorocholine PET for Breast Cancer Diagnosis

Unknown status·NNational Taiwan University Hospital·Phase 4·NCT01956409·80 enrolled

Age1 trial

Gadolinium-Based-Contrast-Agents (GBCA) Enhancement During MR Urography

Completed·VVanderbilt University Medical Center··NCT03910114·500 enrolled

Magnetic Resonance Imaging (MRI)1 trial

Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Brain or Spine Diseases in Chinese Patients

Completed· Bayer logo

Bayer·Phase 3·NCT00395460·147 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Magnevist. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Magnevist compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Magnevist. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bayer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Bayer

Magnevist

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Breast1 trial

Central Nervous System1 trial

Myocardial Infarction1 trial

Metastasis1 trial

Magnetic Resonance Imaging1 trial

MPA1 trial

Breast Cancer1 trial

Age1 trial

Magnetic Resonance Imaging (MRI)1 trial

References

Drug Info

Quick Facts

Related News